Restaging after neo-adjuvant chemoradiotherapy for N2 non-small cell lung cancer.
Recent studies have shown that patients who are down-staged via neoadjuvant therapy and undergo resection have a significant increased 5-year survival rate (as high as 40%-50%) when compared with patients who have residual N2 disease. The identification of patients who are N2 negative after the completion of their neoadjuvant therapy is a critical component of proper patient selection for thoracotomy. Some may even argue that it is a necessary step before resection. In this article we review the best ways to restage patients with N2 disease after they have completed their neoadjuvant therapy.
Cerfolio
Robert J
RJ
Section of Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, 703 19th Street S, ZRB 739, Birmingham, AL 35294, USA. rcerfolio@uab.edu
Bryant
Ayesha S
AS
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008207:Lymphatic Metastasis; D008482:Mediastinum; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging
D000970:Antineoplastic Agents